WALVAX(SZ:300142) Xin Lang Cai Jing·2025-10-27 08:44Core Viewpoint - Watson Bio has received clinical trial approval for its respiratory syncytial virus mRNA vaccine, developed in collaboration with Fudan University and Shanghai Bluebird Biopharmaceuticals, marking a significant step in the company's vaccine development efforts [1] Group 1: Vaccine Development - The mRNA vaccine is based on an independently developed mRNA vaccine technology platform aimed at preventing lower respiratory tract diseases caused by respiratory syncytial virus infections [1] - Currently, there are three respiratory syncytial virus vaccines available in foreign markets, while no similar products have been approved in China [1] Group 2: Clinical Trial and Market Impact - The vaccine has been approved to enter clinical trials; however, it is noted that this approval will not significantly impact the company's performance for the current fiscal year [1] - There remains uncertainty regarding the results of the subsequent confirmatory Phase III clinical trials and the drug application for market approval [1]